KSKristy Shield-Artin

Kristy Shield-Artin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristy Shield-Artin has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial

    by Katrin M. Sjoquist, Alexander Dobrovic, Kristy P. Robledo, Ksenija Nesic, Sally Baron-Hay, Sumitra Ananda, Nicole McCarthy, Jeffrey Goh, Christopher Steer, Nick Murray, et al.

    Background: Homologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (me BRCA1 ) or RAD51C (me RAD51C ) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD. Methods: Single-arm phase 2 trial of olaparib 300 mg orally twice daily. Tumour me BRCA1/ me RAD51C determined by methylation-sensitive, high-resolution melting PCR and targeted sequencing. Unmethylated cases underwent HR gene mutation testing. Primary outcome: objective tumour response rate (OTRR) at 6 months(m). Secondary outcomes: progression-free survival (PFS), OTRR according to HR gene aberration, and safety. Results: Total 22 enrolled: promoter methylation detected in 8/15 HGSOC and 5/7 TNBC, and pathogenic variants (PV) in non- BRCA HR genes. OTRR at 6 m was 40% HGSOC and 0% TNBC. OTRR was 38% in methylated cases vs 43% for other HRD. 6 m/12 m PFS were 53% / 25% (HGSOC), and 17% / 0% (TNBC). Conclusions: Olaparib demonstrated activity in HGSOC beyond gBRCAm, including with me BRCA1 or gRAD51C PV. Olaparib had limited activity in pre-treated TNBC. Effects of prior chemotherapy on me BRCA1/ me RAD51C require exploration to improve patient selection for PARPi. Clinical trials registration: Australian New Zealand Clinical Trials Registry Registration number ACTRN 12617000855325.

  • Open Access

    Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

    by Chee Khoon Lee, Apriliana E. R. Kartikasari, Nirashaa T. Bound, Katherine E. Francis, Kristy Shield-Artin, Justin Bedo, Ksenija Nesic, Katrina Diamante, Rachel L. O’cOnnell, Mutsa Madondo, et al.

    SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n = 114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines. Priming with olaparib, or cyclophosphamide-olaparib, followed by durvalumab-olaparib, are both associated with longer PFS compared to olaparib monotherapy, but do not reach the pre-specified primary endpoint of 36-week trial threshold (PFS36). PFS36 rates are 47.4% (95% CI, 31.0-62.1; olaparib priming then olaparib-durvalumab), 48.7% (32.5-63.2; olaparib-cyclophosphamide then olaparib-durvalumab) and 35.1% (20.4-50.3; olaparib monotherapy). PFS is significantly longer for the homologous recombination deficient (N = 71) as compared to the proficient (HRP) (N = 29) subgroups (Hazard Ratio (HR) 0.55, 0.35-0.87). CUP-CC+ subgroup (N = 58) has a significantly longer PFS (HR 0.31, 0.19-0.49) than CUP-CC- (N = 46). Future studies should investigate whether CUP-CC has the potential to personalize poly (ADP-ribose) polymerase inhibitor therapies for patients who are BRCA wild-type, including HRP patients.


  • Oligomerization‐driven MLKL ubiquitylation antagonizes necroptosis

    by Zikou Liu, Laura F Dagley, Kristy Shield‐Artin, Samuel N Young, Aleksandra Bankovacki, Xiangyi Wang, Michelle Tang, Jason Howitt, Che A Stafford, Ueli Nachbur, et al.

    EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.


  • Open Access

    Oligomerization-driven MLKL ubiquitylation antagonises necroptosis

    by Zikou Liu, Laura F. Dagley, Kristy Shield-Artin, Samuel N. Young, Aleksandra Bankovacki, Xiangyi Wang, Michelle Tang, Jason Howitt, Che A. Stafford, Ueli Nachbur, et al.

    Mixed lineage kinase domain-like (MLKL) is the executioner in the caspase-independent form of programmed cell death called necroptosis. Receptor Interacting serine/threonine Protein Kinase 3 (RIPK3) phosphorylates MLKL, triggering MLKL oligomerization, membrane translocation and membrane disruption. MLKL also undergoes ubiquitylation during necroptosis, yet neither the mechanism nor significance of this event have been demonstrated. Here we show that necroptosis-specific, multi-mono-ubiquitylation of MLKL occurs following its activation and oligomerization. Ubiquitylated MLKL accumulates in a digitonin insoluble cell fraction comprising plasma/organellar membranes and protein aggregates. This ubiquitylated form is diminished by a plasma membrane located deubiquitylating enzyme. MLKL is ubiquitylated on at least 4 separate lysine residues once oligomerized, and this correlates with proteasome- and lysosome-dependent turnover. Using a MLKL-DUB fusion strategy, we show that constitutive removal of ubiquitin from MLKL licences MLKL auto-activity independent of necroptosis signalling in mouse and human cells. Therefore, besides its role in the kinetic regulation of MLKL-induced death following an exogenous necroptotic stimulus, ubiquitylation also contributes to the restraint of basal levels of activated MLKL to avoid errant cell death.